Mostrando 6 resultados de: 6
Filtros aplicados
Subtipo de publicación
Article(6)
Publisher
Cancer Biology and Therapy(2)
Molecular Immunology(2)
Bionatura(1)
Clinical Cancer Research(1)
1E10 anti-idiotype vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients
ArticleAbstract: Conventional treatment of non-small cell lung cancer (NSCLC) has apparently reached a plateau of effPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Aguirre F., Alfonso S., Alonso D.F., Barroso M.C., Carmen Elena Viada, De La Torre A.V., Díaz R.M., Gabri M.R., Gómez R., Hernández A.M., Macías A.E., Pérez K., Pérez R., Rodríguez J., Santiesteban E.R., Suárez E., Toledo D., Vázquez A.M.Fuentes:scopusA monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells
ArticleAbstract: P3 (IgM-κ) is a monoclonal antibody (mAb) reacting with N-glycolyl neuraminic acid (NeuGc)-containinPalabras claves:H-CDR3, Idiotype, Monoclonal antibody, N-Glycolyl neuraminic acidAutores:Mier E., Perez A., Rodríguez R., Santiago Nelson Vispo, Vázquez A.M.Fuentes:scopusA randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients
ArticleAbstract: Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated gangliPalabras claves:Autores:Alfonso S., Areces F., Carmen Elena Viada, Cepeda M., Chong E., De La Torre A.V., Flores Y.I., García E., Gonzalez Z., Guerra P.P., Hernández A.M., Hernández M., Macías A.E., Mazorra Z., Mendoza I.C., Ortiz R.A., Pérez K., Pérez R., Santiesteban E.R., Tania Crombet, Toledo D., Valdes-Zayas A., Vázquez A.M.Fuentes:scopusActive immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: Report of a phase I trial
ArticleAbstract: 1E10 is an anti-idiotype murine monoclonal antibody (Ab2 MAb) specific to an Ab1 MAb which reacts wiPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Alfonso A.M., Alonso D.F., Bárbara Wilkinson, Combet T., De La Torre A.V., Díaz A., Díaz R.M., Gabri M.R., Neninger Vinageras E., Pérez R., Rives R., Saurez G., Vázquez A.M.Fuentes:scopusGangliosides, Ab1 and Ab2 antibodies. I. Towards a molecular dissection of an idiotype-anti-idiotype system
ArticleAbstract: This report is focused on the molecular basis for the interaction of a monoclonal antibody (mAb) andPalabras claves:Anti-idiotypic antibodies, H-CDR, N-Glycolyl-gangliosidesAutores:González M., López-Requena A., Mateo de Acosta C., Moreno E., Pérez R., Puchades Y., Santiago Nelson Vispo, Talavera A., Vázquez A.M.Fuentes:scopusSecurity 1E10 anti-idiotypic vaccine in patients with tumors of different locations
ArticleAbstract: Cancer is a leading cause of death in Cuba and the world. Lung cancer is the leading cause of death,Palabras claves:Anti-idiotypic, Breast, Cáncer, COLON, Non-small cell lung vaccine, security, Small cell lungAutores:Alfonso S., Carmen Elena Viada, García E., Guerra P.P., Hernández M., Macías A.E., MARTHA FORS, Martha M. Fors-López, Mendoza I.C., Neninger Vinageras E., Pérez Ruiz L., Santiesteban E.R., Vázquez A.M.Fuentes:googlescopus